Tags

Type your tag names separated by a space and hit enter

Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.

Abstract

To evaluate long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma, a prospective study was conducted during 2005-2006 influenza season in six public pediatric clinics in Milan and surroundings, Northern Italy. A single dose (0.5 ml) of a virosomal subunit inactivated influenza vaccine (Inflexal V) was injected in 106 asthmatic children aged 3-9 years. Serum hemagglutinin inhibition antibody titers were determined against the recommended influenza strains A/New Caledonia (H1N1), A/California (H3N2), and B/Shanghai (B), at pre-vaccination and 1 and 6 months after vaccination. Seroconversion rate (95% CI) against the strains A/H1N1, A/H3N2 and B was, respectively, 78% (68.6-85.7), 57% (46.7-66.9) and 66% (55.8-71.2) at 1 month. Seroprotection (titer> or =40) rate for A/H1N1, A/H3N2 and B was, respectively, 87% (77.8-92.2), 82% (72.6-89.7) and 90% (82.6-94.8) at 1 month and 74% (64.3-82.3), 77% (67.5-84.8), and 77% (67.5-84.8) at 6 months. Seroprotection rate was high and persistent (>95%) in children with pre-existing antibodies (titer> or =10) at pre-vaccination for any specific strain. In children without pre-existing antibodies, seroprotection rate for A/H1N1, A/H3N2 and B was, respectively, 67.6%, 66.7% and 74.4% at 1 month, and 35.1%, 56.2% and 41.0% at 6 months after vaccination. Vaccine was well tolerated. These results indicate that in unvaccinated children with asthma vaccination with a single dose of virosomal-adjuvanted influenza vaccine is well tolerated and effective as a whole. However, while immunity response and persistence are excellently high in children with pre-existing antibodies, in children naive for the antigens the immune parameters are lower at 6 months after vaccination.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Pediatrics, University of Milan, Luigi Sacco Hospital, Via GB Grassi 74, 20157 Milan, Italy. gianvincenzo.zuccotti@unimi.it

    , , , , , , , , , , ,

    Source

    Vaccine 25:37-38 2007 Sep 17 pg 6692-8

    MeSH

    Acute Disease
    Antibodies, Viral
    Asthma
    Child
    Child, Preschool
    Humans
    Influenza A Virus, H1N1 Subtype
    Influenza A Virus, H3N2 Subtype
    Influenza B virus
    Influenza Vaccines
    Prospective Studies
    Time Factors
    Treatment Outcome
    Vaccines, Inactivated
    Vaccines, Subunit
    Virosomes

    Pub Type(s)

    Journal Article
    Multicenter Study

    Language

    eng

    PubMed ID

    17697730

    Citation

    Zuccotti, Gianvincenzo, et al. "Long-term Immunogenicity of a Virosomal Subunit Inactivated Influenza Vaccine in Children With Asthma." Vaccine, vol. 25, no. 37-38, 2007, pp. 6692-8.
    Zuccotti G, Amendola A, Viganò A, et al. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma. Vaccine. 2007;25(37-38):6692-8.
    Zuccotti, G., Amendola, A., Viganò, A., Pariani, E., Zappa, A., Pogliani, L., ... Radaelli, G. (2007). Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma. Vaccine, 25(37-38), pp. 6692-8.
    Zuccotti G, et al. Long-term Immunogenicity of a Virosomal Subunit Inactivated Influenza Vaccine in Children With Asthma. Vaccine. 2007 Sep 17;25(37-38):6692-8. PubMed PMID: 17697730.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma. AU - Zuccotti,Gianvincenzo, AU - Amendola,Antonella, AU - Viganò,Alessandra, AU - Pariani,Elena, AU - Zappa,Alessandra, AU - Pogliani,Laura, AU - Giacomet,Vania, AU - Savarino,Antonino, AU - Podestà,Alberto, AU - Rottoli,Amilcare, AU - Tanzi,Elisabetta, AU - Zanetti,Alessandro, AU - Radaelli,Giovanni, Y1 - 2007/07/27/ PY - 2006/12/27/received PY - 2007/06/04/revised PY - 2007/07/10/accepted PY - 2007/8/19/pubmed PY - 2007/11/9/medline PY - 2007/8/19/entrez SP - 6692 EP - 8 JF - Vaccine JO - Vaccine VL - 25 IS - 37-38 N2 - To evaluate long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma, a prospective study was conducted during 2005-2006 influenza season in six public pediatric clinics in Milan and surroundings, Northern Italy. A single dose (0.5 ml) of a virosomal subunit inactivated influenza vaccine (Inflexal V) was injected in 106 asthmatic children aged 3-9 years. Serum hemagglutinin inhibition antibody titers were determined against the recommended influenza strains A/New Caledonia (H1N1), A/California (H3N2), and B/Shanghai (B), at pre-vaccination and 1 and 6 months after vaccination. Seroconversion rate (95% CI) against the strains A/H1N1, A/H3N2 and B was, respectively, 78% (68.6-85.7), 57% (46.7-66.9) and 66% (55.8-71.2) at 1 month. Seroprotection (titer> or =40) rate for A/H1N1, A/H3N2 and B was, respectively, 87% (77.8-92.2), 82% (72.6-89.7) and 90% (82.6-94.8) at 1 month and 74% (64.3-82.3), 77% (67.5-84.8), and 77% (67.5-84.8) at 6 months. Seroprotection rate was high and persistent (>95%) in children with pre-existing antibodies (titer> or =10) at pre-vaccination for any specific strain. In children without pre-existing antibodies, seroprotection rate for A/H1N1, A/H3N2 and B was, respectively, 67.6%, 66.7% and 74.4% at 1 month, and 35.1%, 56.2% and 41.0% at 6 months after vaccination. Vaccine was well tolerated. These results indicate that in unvaccinated children with asthma vaccination with a single dose of virosomal-adjuvanted influenza vaccine is well tolerated and effective as a whole. However, while immunity response and persistence are excellently high in children with pre-existing antibodies, in children naive for the antigens the immune parameters are lower at 6 months after vaccination. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/17697730/Long_term_immunogenicity_of_a_virosomal_subunit_inactivated_influenza_vaccine_in_children_with_asthma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(07)00786-4 DB - PRIME DP - Unbound Medicine ER -